logo

For the Inventor, By the Inventor

Rome, Italy

Mario Materazzi

USPTO Granted Patents = 13

Average Co-Inventor Count = 4.3

ph-index = 7

Forward Citations = 116(Granted Patents)


Location History:

  • Roma RM, IT (1991)
  • Rome, IT (1985 - 2000)

Company Filing History:

goldMedal12 out of 18 
 
Polifarma S.p.a.
 patents
silverMedal1 out of 832,718 
Other
 patents

Years Active: 1985-2000

Loading Chart...
13 patents (USPTO):Explore Patents
1. 6057297 - Inhibitor compounds of zinc-dependent metalloproteinases associated with (2000-05-02),
2. 5846755 - Method for determining the therapeutic activity of metalloproteinase (1998-12-08),
3. 5447951 - Method for reducing the level of glucocorticoids in the blood and (1995-09-05),
4. 5210215 - Tryptophane and 3-indolepyruvic acid, methods of production therefor (1993-05-11),
5. 5190948 - Use of uridine in the pharmacological treatment of the peripheral (1993-03-02),
6. 5143903 - Method of treatment with tripeptide pharmaceutical compositions as (1992-09-01),
7. 5091172 - Cosmetic use of 3-indolepyruvic acid (1992-02-25),
8. 5075329 - Use of 3-indolepyruvic acid as a pharmaceutical agent for the inhibition (1991-12-24),
9. 5002963 - 3-indolepyruvic acid derivatives and pharmaceutical use thereof (1991-03-26),
10. 4960759 - Pharmacological use of uridine in the treatment of nervous disorders (1990-10-02),
11. 4808728 - Production of indolepyruvic acid and the 5-hydroxy derivative thereof (1989-02-28),
12. 4619916 - Tripeptide compounds containing pyroglutamic acid and tryptophan, (1986-10-28),
13. 4551471 - Use of 3-indolepyruvic acid for increasing serotonin (1985-11-05),

Title: Innovations of Mario Materazzi

Introduction

Mario Materazzi is a prominent inventor based in Rome, Italy. He has made significant contributions to the field of metalloproteinase research, holding a total of 13 patents. His work focuses on developing compounds that can inhibit zinc-dependent metalloproteinases, which are crucial in treating various pathological conditions.

Latest Patents

Among his latest patents are innovative compounds designed to inhibit zinc-dependent metalloproteinases. These include peptidomimetic compounds capable of treating pathological conditions associated with the activation of endogenous metalloproteinases in mammals. Additionally, he has developed a method for determining the therapeutic activity of metalloproteinase inhibitors, which assesses the potential of peptidomimetic compounds in addressing pathological conditions in both humans and animals.

Career Highlights

Mario has worked with notable companies, including Polifarma S.p.a. His career is marked by a commitment to advancing medical science through innovative research and development.

Collaborations

He has collaborated with esteemed colleagues such as Giovanni Di Stazio and Giovanna De Luca, contributing to a rich exchange of ideas and expertise in his field.

Conclusion

Mario Materazzi's work exemplifies the impact of innovation in medical research, particularly in the development of therapeutic agents targeting metalloproteinases. His contributions continue to influence the landscape of treatment options available for various diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…